Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia.

Annals of hematology - 1 Jun 2024

Jebanesan Daniel Zechariah Paul, Illangeswaran Raveen Stephen Stallon, Rajamani Bharathi M, Vidhyadharan Rakhi Thalayattu, Das Saswati, Bijukumar Nayanthara K, Balakrishnan Balaji, Mathews Vikram, Velayudhan Shaji R, Balasubramanian Poonkuzhali

Abstract excerpt

De novo acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) have worse treatment outcomes. Arsenic trioxide (ATO) used in the treatment of acute promyelocytic leukemia (APL) has been reported to be effective in degrading the FLT3 protein in AML cell lines and sensitizing non-APL AML patient samples in-vitro. We have previously reported that primary cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arsenic Trioxide
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to NF-E2-Related Factor 2

Share to Signal Transduction

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 38630133
DOI: 10.1007/s00277-024-05742-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia.PMID 38630133Read ↗

Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.Semantic proximity Read ↗

Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosisSemantic proximity Read ↗

Nuclear factor Nrf2 promotes glycosidase OGG1 expression by activating the AKT pathway to enhance leukemia cell resistance to cytarabineSemantic proximity Read ↗

The role of NRF2 in acute myeloid leukaemia (AML)Semantic proximity Read ↗

Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia through inhibiting MSH2Semantic proximity Read ↗

Arsenic trioxide resistance in acute promyelocytic leukemia: More to it than PML mutationsSemantic proximity Read ↗

Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib TreatmentsSemantic proximity Read ↗

Molecular Targets of Arsenic Trioxide in Malignant CellsSemantic proximity Read ↗

Roles of Glutathione and AP-1 in the Enhancement of Vitamin D-induced Differentiation by Activators of the Nrf2 Signaling Pathway in Acute Myeloid Leukemia CellsSemantic proximity Read ↗

Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2.Semantic proximity Read ↗

Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD.Semantic proximity Read ↗

DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.